HIGHBuilt-inPipeline
JADE101
“10-K Item 1A: 'We are substantially dependent on the success of JADE101, and our current and anticipated future clinical trials of such product candidate may not be successful.'”
JBIO · Concentration risk · 10-K extracted
Jade Biosciences (JBIO) concentration risks
Updated
The most significant concentration Jade Biosciences discloses is JADE101, classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: Jade Biosciences’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
At a glance
Disclosed-size breakdown · 2 disclosed concentrations
HIGH1
MEDIUM1
LOW0
Disclosed concentrations
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
MEDIUMOutside partySupplier
Paragon Therapeutics collaboration
“10-K Item 1A: 'We rely on collaborations and licensing arrangements with third parties, including Paragon Therapeutics, Inc. (“Paragon”).'”
TrendMatrix Research · concentration synthesis
What these concentrations mean together
updated 2026-07-06Jade Biosciences carries two concentration exposures that compound each other. The company is substantially dependent on the success of JADE101, with anticipated future clinical trials that may not succeed — a structural risk reflecting its position as a clinical-stage company with a narrow pipeline rather than a diversified product base. Layered on top is a dependency exposure: Jade relies on collaborations and licensing arrangements with third parties, including Paragon Therapeutics, for the arrangements that support its programs. While the pipeline concentration sits in the HIGH band and the Paragon relationship in the MEDIUM band, the two interact — a disruption to the Paragon collaboration could affect the very programs, including JADE101, that the company is most dependent on succeeding. This is a case where a single clinical or partnership setback could have outsized effects on the investment case, since there is no revenue diversification to offset it. For an educated investor, the read-through is that Jade's near-term trajectory hinges jointly on JADE101's clinical progress and the continuity of the Paragon arrangement, making both worth tracking together rather than in isolation. Both exposures are disclosed in the most recent 10-K.
For the engine’s reasoning on JBIO’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
Industry peers · Biotechnology
Peer concentration profile
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| ACAD | ACADIA Pharmaceuticals Inc. | 2 | 0 | 0 | 2 |
| ABUS | Arbutus Biopharma Corporation | 1 | 1 | 0 | 2 |
| JBIO● | Jade Biosciences, Inc. | 1 | 1 | 0 | 2 |
| ABSI | Absci Corporation | 1 | 0 | 0 | 1 |
| ABCL | AbCellera Biologics Inc. | 0 | 0 | 0 | 0 |
| ACHV | Achieve Life Sciences, Inc. | 0 | 0 | 0 | 0 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.